Brar Tripti, Baheti Saurabh, Marino Michael J, Kita Hirohito, Lal Devyani
Department of Otolaryngology-Head & Neck Surgery, Mayo Clinic, Phoenix, AZ, USA.
Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Am J Rhinol Allergy. 2023 Nov;37(6):692-704. doi: 10.1177/19458924231193526. Epub 2023 Aug 16.
Epigenetics studies mechanisms such as DNA methylation, histone modifications, non-coding RNAs, and alternative polyadenylation that can modify gene activity without changing the underlying DNA nucleotide base-pair structure. Because these changes are reversible, they have potential in developing novel therapeutics. Currently, seven pharmaceutical agents targeting epigenetic changes are FDA approved and commercially available for treatment of certain cancers. However, studies investigating epigenetics in chronic rhinosinusitis (CRS) have not been undertaken previously in the United States.
The goal of this study was to investigate sinonasal DNA methylation patterns in CRS versus controls, to discern environmentally-induced epigenetic changes impacting CRS subjects.
Ethmoidal samples from CRS and inferior turbinate mucosal tissue samples from controls without CRS were studied. DNA methylation was studied by Reduced Representation Bisulfite Sequencing. RADMeth® biostatistical package was used to identify differentially methylated regions (DMRs) between CRS and controls. Ingenuity Pathway analysis of DMRs was performed to identify top upstream regulators and canonical pathways. Ninety-three samples from 64 CRS subjects (36 CRSwNP; 28 CRSsNP) and 29 controls were studied. CRS and control samples differed in 13 662 CpGs sites and 1381 DMRs. Top upstream regulators identified included: 1. CRS versus controls: TGFB1, TNF, TP53, DGCR8, and beta-estradiol. 2. CRSwNP versus controls: TGFB1, CTNNB1, lipopolysaccharide, ID2, and TCF7L2. 3. CRSsNP versus controls: MYOD1, acetone, ID2, ST8SIA4, and LEPR.
Differential patterns of methylation were identified between controls and CRS, CRSwNP, and CRSsNP. Epigenetic, environmentally-induced changes related to novel, inflammatory, immunologic, and remodeling pathways appear to affect epithelial integrity, cell proliferation, homeostasis, vascular permeability, and other yet uncharacterized pathways and genes.
表观遗传学研究诸如DNA甲基化、组蛋白修饰、非编码RNA和可变聚腺苷酸化等机制,这些机制可在不改变潜在DNA核苷酸碱基对结构的情况下改变基因活性。由于这些变化是可逆的,它们在开发新型疗法方面具有潜力。目前,有七种针对表观遗传变化的药物已获美国食品药品监督管理局(FDA)批准并可用于治疗某些癌症。然而,此前美国尚未开展过关于慢性鼻-鼻窦炎(CRS)表观遗传学的研究。
本研究的目的是调查CRS患者与对照组鼻窦DNA甲基化模式,以识别影响CRS患者的环境诱导表观遗传变化。
研究了CRS患者的筛骨样本和无CRS的对照组下鼻甲黏膜组织样本。采用简化代表性亚硫酸氢盐测序研究DNA甲基化。使用RADMeth®生物统计学软件包识别CRS患者与对照组之间的差异甲基化区域(DMR)。对DMR进行 Ingenuity Pathway分析以识别顶级上游调节因子和经典通路。研究了64例CRS患者(36例CRSwNP;28例CRSsNP)和29例对照组的93个样本。CRS患者与对照组样本在13662个CpG位点和1381个DMR存在差异。识别出的顶级上游调节因子包括:1. CRS患者与对照组:转化生长因子β1(TGFB1)、肿瘤坏死因子(TNF)、p53、DGCR8和β-雌二醇。2. CRSwNP与对照组:TGFB1、β-连环蛋白(CTNNB1)、脂多糖、ID2和TCF7L2。3. CRSsNP与对照组:肌细胞生成素(MYOD1)、丙酮、ID2、ST8唾液酸α-2,6-唾液酸转移酶4(ST8SIA4)和瘦素受体(LEPR)。
在对照组与CRS、CRSwNP和CRSsNP之间识别出了不同的甲基化模式。与新的、炎症、免疫和重塑通路相关的表观遗传、环境诱导变化似乎影响上皮完整性、细胞增殖、内环境稳定、血管通透性以及其他尚未明确的通路和基因。